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ABSTRACT 
 
Background and Objectives: Nowadays, high-level aminoglycosides and ampicillin resistant Enterococcus species are 
among the most common causes of nosocomial infections. The present study was conducted to determine the prevalence 
of high-level resistance to aminoglycosides and ampicillin among clinical isolates of Enterococcus species in Ardabil, Iran. 
Materials and Methods: In this cross–sectional study, a total of 111 Enterococcus species were collected from different 
clinical specimens between 2013 and 2015. Enterococcus species were identified using standard phenotypic and genotypic 
methods. BHI agar screen and agar dilution methods were used for detection of high-level gentamicin and streptomycin 
resistance (HLGR and HLSR) and minimal inhibitory concentration (MIC) of ampicillin, respectively.
Results: Of 111 clinical isolates, 59 (53.2%) and 25 (22.5%) isolates were E. faecalis and E. faecium, respectively, based on 
the PCR results. Totally, 60.3% and 56.7% of isolates were HLGR and HLSR, respectively, as well as 51.35% were HLGR 
plus HLSR. Among HLGR isolates, 36 (61.01%), 18 (72%) and 13 (48.14%) were E. faecium, E. faecalis and non-faecalis 
non-faecium species, respectively. Among HLSR isolates, 33 (55.93%), 16 (64%) and 14 (51.85%) were E. faecalis, E. fae-
cium and non-faecalis non-faecium species, respectively. All HLGR isolates contained aac(6´)Ie-aph(2″)Ia gene. Overall, 
the prevalence of high-level ampicillin resistance among Enterococcus species was 17.1%. For E. faecalis, E. faecium and 
non-faecalis non-faecium species, ampicillin resistance rates were as follows: 11 (40.74%), 7 (28%) and 1 (1.69%), respec-
tively. For aminoglycoside antibiotics, the resistance rate was significantly higher in E. faecium isolates and for ampicillin it 
was higher in E. faecalis isolates. 
Conclusion: The frequency of high-level aminoglycoside resistant enterococcal isolates in our hospital was high and signif-
icant ampicillin resistance was noticed. This would require routine testing of enterococcal isolates for HLAR and ampicillin 
susceptibility.
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INTRODUCTION
Enterococcus species have been ranked as the sec-
ond to third most common organisms responsible 
for nosocomial infections, especially in critically ill 
patients or individuals who received multiple anti-
biotics (1). In clinical practice, most of non-invasive 
and uncomplicated enterococcal infections are usu-
ally cured using a single antibiotic regimen. While, 
to achieve an efficient bactericidal activity, combi-
nation therapy is needed for treating deep-seated 
enterococcal infections (such as endocarditis) (2). 
The most common therapy regimen is a combina-
tion of a cell wall active agent (e.g., ampicillin and 
vancomycin) and an aminoglycoside, gentamicin or 
streptomycin (2). These agents act synergistically to 
http://ijm.tums.ac.ir
enhance killing of the bacteria, since the beta-lactam 
agents damage the cell wall and increase the entry 
of the aminoglycosides into the cell (3). Generally, 
penicillins (e.g., ampicillin) have the highest activity, 
carbapenems slightly lower and cephalosporins and 
aztreonam have the lowest activity (4). Enterococ-
cus spp. show low-level intrinsic resistance against 
beta-lactam and aminoglycoside antibiotics (3). The 
major categories of acquired antibiotic resistance in 
enterococci include high-level penicillin and ampi-
cillin resistance, high-level aminoglycoside resis-
tance (HLAR) and vancomycin resistance (3, 4). The 
acquisition of these types of resistance eliminates the 
synergistic effect of combination therapy (2).  
The aim of this study was to determine the fre-
quency of high-level resistance to aminoglycosides 
and ampicillin among enterococcal isolates collected 
from different clinical specimens in an Iranian hos-
pital.
 
MATERIALS AND METHODS
 Media and chemicals. DNP™ Genomic DNA 
Extraction Kit was purchased from Cinagen Com-
pany (Cinagen, Iran). AccuPower™ PCR PreMix Kit 
and oligonucleotide primers were obtained from Bi-
oneer Company (Daejon, South Korea). Gentamicin, 
streptomycin and ampicillin powders were purchased 
from Bio Basic Company (Bio Basic Inc. Canada). 
Brain Hart Infusion Agar (BHI) was obtained from 
Difco Laboratories (Detroit, MI, USA) and Tryp-
ticase Soy Broth (TSB), Blood Agar, Bile Esculin 
Agar (BEA) and Mueller Hinton Agar (MHA) were 
purchased from Himedia laboratories (Mumbai, In-
dia).
Isolation and identification of bacteria. From 
November 2013 to September 2015, a total of 111 en-
terococci strains were isolated from different clini-
cal specimens collected from patients admitted to a 
referral teaching hospital affiliated to Ardabil Uni-
versity of Medical Sciences. Isolates were examined 
by conventional phenotypic methods at the genus 
level. E. faecium and E. faecalis were identified us-
ing PCR analysis of the ddl gene as described previ-
ously (1, 5). E. faecalis ATCC 29212 and E. faecium 
ATCC 51559 were used as controls. Identified iso-
lates were stored at -80ºC in TSB containing 15% 
glycerol.
Antimicrobial susceptibility testing. High-lev-
el aminoglycosides resistance (HLAR), gentamicin 
(HLGR) and streptomycin (HLSR), were determined 
using BHI agar screen method (1). Testing for min-
imum inhibitory concentration (MIC) of ampicillin 
was performed by standard agar dilution method 
(concentration rang: 0.12-1024 µg/ml) (1). Resistance 
to ampicillin was defined as MIC ≥ 16 (µg/ml).
Antimicrobial susceptibility testing was per-
formed and interpreted according to the guidelines 
of the Clinical and Laboratory Standards Institute 
(CLSI) (6). Enterococcus faecalis ATCC 29212 was 
used as control strain.
PCR amplification of HLGR resistance gene. 
The presence of aac(6´)Ie-aph(2″)Ia gene in the ge-
nome of HLGR isolates was detected using PCR 
method as reported earlier (10, 12). 
Statistical analysis. Chi-square test was used to 
compare the prevalence of HLAR strains between 
specimen type and hospital wards. 
RESULTS
   In the present study, a total of 111 Enterococcus 
species were isolated from different clinical speci-
mens from patients who referred to Imam Khomeini 
Hospital in Ardabil province. Totally, 61 (54.9%) and 
50 (45.1%) isolates were collected from female and 
male patients, respectively. Enterococci isolates were 
collected from urine (n=87), blood (n=21), wound 
(n=2) and sputum (n=1) specimens. 
   PCR analysis of ddl gene. Identification of E. fae-
calis and E. faecium species was performed by am-
plification of ddl gene using PCR method. According 
to the PCR results, 59 (53.2%) and 25 (22.5%) iso-
lates were E. faecalis and E. faecium, respectively, as 
well as 27 (24.3%) isolates belonged to non-faecalis 
non-faecium Enterococcus species.
  Detection of HLGR and HLSR strains. Total-
ly, 60.3% and 56.7% of isolates were HLGR and 
HLSR, respectively, as well as 51.35% were HLGR 
plus HLSR. Among HLGR isolates, 36 (61.01%), 18 
(72%) and 13 (48.14%) were E. faecium, E. faecalis 
and non-faecalis non-faecium species, respectively. 
Among HLSR isolates, 33 (55.93%), 16 (64%) and 14 
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(51.85%) were E. faecalis, E. faecium and non-fae-
calis non-faecium species, respectively. Statistically, 
there was no significant difference between the prev-
alence of HLGR and HLSR phenotypes in Entero-
coccus spp. (P > 0.05) (Fig. 1). All HLGR isolates 
were contained the aac(6´)Ie-aph(2″)Ia gene. 
   The prevalence of HLGR and HLSR phenotypes 
was significantly different according to the hospital 
wards in both E. faecium and E. faecalis species (P 
< 0.001). The majority of them were isolated from 
patients who admitted to internal medicine ward, in-
fectious diseases ward and outpatient clinic, respec-
tively (Table 1). However, statistically there was no 
significant difference in distribution of Enterococcus 
spp. between wards, except for HLGR E. faecium 
isolates in infectious disease ward and HLGR and 
HLSR non-faecalis non-faecium species in internal 
medicine ward (P < 0.05). 
    The majority of HLAR Enterococcus species were 
isolated from urine specimens (P < 0.001). However, 
there was no significant difference between distribu-
tion of HLAR Enterococcus species and specimen 
type (P > 0.05) (Table 2).
   Determining MIC for ampicillin. In this study, 
MIC of ampicillin was determined using agar dilu-
Fig. 1. Prevalence of HLAR among Enterococcus species isolated from clinical specimens
HLAR; High level aminoglycoside resistance, HLGR; High level gentamicin resistance, HLSR; High level streptomycin 
resistance
tion method. Totally, 19 (17.1%) out of 111 enterococ-
ci isolates showed high-level resistance to ampicil-
lin (MIC ≥ 16 µg/mL). Ampicillin resistance in E. 
faecalis isolates was found in 11 (18.6%) out of 59 
isolates. The MIC values for ampicillin resistant E. 
faecalis isolates were ranged from 32-512 µg/mL [32; 
1 (9.10%), 64; 1 (9.10%), 256; 4 (36.36%) and 512; 5 
(45.45%)]. Twenty-eight percent (7/25) of E. faecium 
isolates with MIC values from 32 to 1024 µg/mL [32; 
2 (28.57%), 64; 1 (14.28%), 256; 1 (14.28%), 512; 4 
(45.45%) and 1024; 1 (14.28%)] were found to be am-
picillin resistant. In non-faecalis and non-faecium 
enterococci 3.6% of isolates were ampicillin resistant 
(MIC; 32 µg/mL). 
DISCUSSION
   Nowadays, acquired high-level ampicillin resis-
tance in Enterococcus species is an increasing glob-
al concern. Epidemiology of enterococci resistant 
to ampicillin varies among hospitals and countries. 
In the USA and Europe, the majority of nosocomial 
invasive enterococci isolates are resistant to ampi-
cillin (7). Ampicillin resistance is most commonly 
seen in E. faecium isolates (7). Accordingly, in this 
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Table 1. Prevalence of HLAR among Enterococcus species isolated from clinical specimens in different hospital ward
Hospital ward
Internal medicine
ICU 
Infectious disease
Outpatient clinic
Emergency 
Cardiology 
Cardiothorax
Coronary care unit (CCU)
E. faecalis 
(n = 36)
n (%)
13 (36.11)
3 (8.33)
6 (16.70)
6 (16.70)
3 (8.33)
2 (5.55)
1 (2.80)
1 (2.77)
HLGR
E. faecium 
(n = 18)
n (%)
9 (50)
1 (5.6)
4 (22.20)*
2 (11.10)
1 (5.6)
-
-
1 (5.6)
non-faecalis 
non-faecium 
(n = 13) 
n (%)
9(69.23 )*
-
1(7.7)
2(15.40)
-
-
1(7.7)
-
E. faecalis
(n = 33)
n (%)
12 ( 36.37)
3 (9.10)
6 (18.2)
6 (18.2)
3 (9.10)
1 (3.03)
1 (3.03)
1 (3.03)
HLSR
E. faecium 
(n = 16)
n (%)
7 (43.75)
2 (12.5)
3 (18.75)
2 (12.5)
1 (6.25)
-
-
1 (6.25)
non-faecalis
non-faecium
(n = 14)
n (%)
9 (64.30)*
-
2 (14.30)
2 (14.30)
-
-
1 (7.14)
-
HLAR
*Statistically significant (P < 0.05)
HLAR; High level aminoglycoside resistance, HLGR; High level gentamicin resistance, HLSR; High level streptomycin 
resistance
Table 2. Prevalence of HLAR among Enterococcus species isolated from clinical specimens based on specimen type
Specimen type
Urine
Blood
Wound
E. faecalis 
(n = 36)
n (%)
31 (86.10)
4 (11.11)
1 (2.80)
HLGR
E. faecium 
(n = 18)
n (%)
15 (83.33)
3 (16.66)
-
non-faecalis 
non-faecium 
(n = 13)
n (%)
1 1(84.61)
2 (15.40)
-
E. faecalis
(n = 33)
n (%)
27 (81.80)
5 (15.15)
1 (3.00)
HLSR
E. faecium 
(n = 16)
n (%)
12 (75)
4 (25)
-
non-faecalis 
non-faecium 
(n = 14)
n (%)
11 (78.60)
3 (21.43)
-
HLAR
HLAR; High level aminoglycoside resistance, HLGR; High level gentamicin resistance, HLSR; High level streptomycin 
resistance
study, resistance to ampicillin in E. faecium (28%) 
was higher than E. faecalis (19%) isolates. Previous-
ly it has been shown that 90%, 84%, 74% and 69% 
of E. faecium recovered from healthcare-associated 
infections in the USA, Argentina, Denmark and Iran 
were ampicillin resistant, respectively (4, 7-9). In Ar-
dabil, the prevalence of ampicillin-resistant E. fae-
cium isolates was significantly lower than the other 
parts of the world as well as Iran (15). Interestingly, 
the prevalence of ampicillin-resistant E. faecalis iso-
lates was high (19%) in this study which is similar to 
Asadollahi et al. report from Iran (17.1%) (15). Giv-
en the negligible incidence of ampicillin-resistant 
E. faecalis isolates in other parts of the world, our 
findings represent a significant increase in ampicil-
lin resistance rate in E. faecalis isolates in Iran. In a 
report from Argentina in 2015, ampicillin resistance 
rate was only 1.8% in E. faecalis isolates (4). While, 
high-level resistance to penicillin and aminopeni-
cillins have not yet been described in non-faecalis 
non-faecium Enterococcus species (4), in this study 
one non-faecalis non-faecium isolate was found to be 
resistant against ampicillin. 
   Recently several antibiotics were introduced to be 
used in combination with ampicillin in the treatment 
of enterococcal invasive infections (2). However, 
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aminoglycoside antibiotics are still the main compo-
nent of combination therapy of enterococcal invasive 
infections (2). With the emergence of high-level re-
sistance, any synergistic effect between aminogly-
cosides and cell wall active agents is lost. In recent 
years, acquired high-level resistance to aminoglyco-
sides increased significantly by the wide spread of 
genes encoding aminoglycoside modifying enzymes 
(AMEs). In a survey conducted in Australia in 2013, 
32.4% of E. faecalis and 61.8% of E. faecium isolates 
showed HLGR phenotype (10). Because of limited 
use of streptomycin, very few studies have recent-
ly studied prevalence of HLSR phenotype among 
Enterococcus species. In a twelve-year surveillance 
in Japan, HLSR phenotype was detected in 18% of 
E. faecalis and 39% of E. faecium isolates in 2016 
(11). Unfortunately, there is no a nationwide surveil-
lance data for HLGR and HLSR phenotypes in Iran. 
However, sporadic studies were reported a HLGR 
phenotype range of 33 to 77.3% in E. faecium and 
25.84% to 89% in E. faecalis isolates. Similarly, 
HLSR phenotype was reported as 27.27% to 90.10% 
and 40.44% to 73.10% in E. faecium and E. faecalis 
isolates, respectively (12-16). In the current study, the 
prevalence of HLGR was observed among 61.01% 
of E. faecalis, 72% of E. faecium, and 48.14% of 
non-faecalis non-faecium species. Additionally, 33 
(55.93%) of E. faecalis, 16 (64%) of E. faecium and 
14 (51.85%) of non-faecalis non-faecium species had 
HLSR phenotype. Similar to other reports around 
the world (11), the proportion of HLGR and HLSR 
were higher in E. faecium compared to E. faecalis 
isolates. In this study, 45.47% and 60% of E. faecalis 
and E. faecium isolates exhibited dually high-level 
gentamicin and streptomycin resistance, respective-
ly, which is similar to findings reported in other stud-
ies (15). As high-level resistance to gentamicin and 
streptomycin is caused by different mechanisms (3), 
these antibiotics can be used surrogate to each other 
in enterococcal infections treatment. Therefore, the 
emergence of isolates with simultaneous resistance 
phenotype, HLGR and HLSR, will limit the thera-
peutic options of enterococcal infections. 
   High-level aminoglycosides resistance is primar-
ily due to the presence of the AMEs. In Enterococ-
cus species, there are several AMEs responsible for 
HLGR and HLSR (1). The aac(6')Ie-aph(2')Ia gene 
is the most prevalent gene encoding a AME which 
causes high-level resistance to aminoglycosides ex-
cept for streptomycin (1). In the present study, we 
examined only the presence of the aac(6')Ie-aph(2')
Ia gene for strains with HLGR. Our findings showed 
that all HLGR isolates were positive for aac(6')Ie-
aph(2')Ia gene. Similar results were reported from 
Iran and other countries (11, 14). Genetic basis for 
HLSR was not further studied in this study.
CONCLUSION
   The frequency of high-level aminoglycoside re-
sistant enterococcal isolates in our hospital was 
high and significant ampicillin resistance was no-
ticed. Therefore, to achieve an optimal therapeutic 
outcome, continuous monitoring is needed through 
routine susceptibility testing of enterococcal isolates 
against aminoglycosides and ampicillin. 
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